RPL27: A Protein Involved in Cell Growth, Apoptosis, Translation and More

Target Name: RPL27

NCBI ID: G6155

RPL27

RPL27: A Protein Involved in Cell Growth, Apoptosis, Translation and More

Ribosomal protein L27 (RPL27) is a protein that plays a critical role in the process of translation of RNA into proteins. It is a large protein with a molecular weight of approximately 180 kDa and is composed of 27 subunits. RPL27 is expressed in most eukaryotic cells and is involved in various cellular processes, including cell growth, apoptosis, and translation.

One of the unique features of RPL27 is its ability to interact with small RNA species, including microRNAs (miRNAs) and small interfering RNA (siRNA). This interaction between RPL27 and these RNA species has important implications for cellular processes, including gene regulation, cell survival, and cell-cell signaling.

In addition to its role in gene regulation, RPL27 has also been shown to play a key role in the process of translation itself. It has been shown to interact with the machinery responsible for translating mRNAs into the cytoplasm, and it has been shown to directly contribute to the process of cytoplasmic translation.

RPL27 is also involved in the regulation of cellular processes that are important for cell survival. For example, it has been shown to play a role in the regulation of cell apoptosis, a process that is important for the control of cellular life and death. In addition, RPL27 has been shown to interact with stress response proteins, which are involved in the regulation of cellular stress responses.

Given its involvement in a wide range of cellular processes, RPL27 is an attractive target for drug development. Many small molecules have been shown to interact with RPL27 and have been identified as potential drugs for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

One of the challenges in developing drugs for RPL27 is the lack of information about its precise mechanism of action. While it is known that RPL27 plays a key role in the regulation of cellular processes, it is not clear exactly how it does this. This lack of information makes it difficult to design drugs that specifically target RPL27 and to understand how different drugs will interact with it.

However, there is some progress being made in the development of drugs for RPL27. For example, a small molecule called U012 has been shown to interact with RPL27 and has been shown to inhibit its activity in cell experiments. Additionally, a team of researchers has used RNA interference technology to knock down RPL27 expression in cell experiments and has shown that this to reduce the levels of cellular RPL27.

While further research is needed to fully understand the mechanism of action of RPL27 and to develop effective drugs for it, its potential role in the regulation of cellular processes makes it an important target for further research and development.

Protein Name: Ribosomal Protein L27

Functions: Component of the large ribosomal subunit (PubMed:12962325, PubMed:23636399, PubMed:25957688, PubMed:25901680, PubMed:32669547). Required for proper rRNA processing and maturation of 28S and 5.8S rRNAs (PubMed:25424902)

The "RPL27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets